TREATMENTS FOR ACUTE MIGRAINE: WHAT’S ON THE HORIZON?Mark Weatherall
BASH Hull 2011
A LITTLE HISTORY...
ergot of rye 1868 salicylic acid 1870s ergotamine 1920s-30s dihydroergotamine (DHE) 1943 triptans 1990s
sumatriptan then riza-, then ele-, then almo-, then
zolmi-, then nara-, and finallyfrovatriptan
WHY DO WE NEED NEW OPTIONS?
poor response to current treatments tolerability issues contraindications
stroke MI/IHD hypertension
WHAT APPROACHES ARE BEING TAKEN?
identify novel neurochemical targets (based on better understanding of migraine pathophysiology)
develop new drugs for known targets develop new modes of delivering existing
drugs develop non-pharmacological treatments
NEW(ISH) NEUROCHEMICAL TARGETS
serotonin subtype receptors calcitonin gene-related peptide (CGRP)
receptors glutamate receptors transient receptor potential vanilloid (TRPV1)
receptors nitric oxide synthesis prostanoid receptors (cortical spreading depression)
THE SEROTONIN RECEPTOR FAMILIES
seven families of serotonin receptors triptans are agonists at 5-HT1B/1D receptors
5-HT1B predominate in meningeal vessel walls
5-HT1D predominate in trigeminal nerve fibres
a specific 5-HT1D agonist (PNU-142633) inhibits PPE potently, but was ineffective in clinical studies ? weak agonist ?? PPE not relevant in migraine
pathogenesis
5-HT1F – A POSSIBLE TARGET?
5-HT1F receptors are found in trigeminal ganglion & TNC; no vasocontrictor activity
LY-334370, a potent 5-HT1F agonist, was effective against migraine, but caused unacceptable SE
Proof-of-concept study of COL-144 (lasmitidan), an oral 5-HT1F agonist, was published in Cephalalgia 2010
CGRP: IS THE FUTURE ‘PANTS’ OR ‘GEPANTS’?
calcitonin gene-related peptide (CRGP), a potent vasodilator, is the most frequently expressed neuropeptide in trigeminal fibres and cell bodies
in primary headaches, there is a clear association between the headache & CRGP release CRGP levels in the jugular vein are increased in
migraine, CH & CPH CRGP levels in the antecubital vein increase in
nitroglycerin-induced migraine; levels correlate with headache intensity
sumatriptan normalises elevated CGRP levels as it terminates a migraine attack
CGRP ANTAGONISTS FOR MIGRAINE? BIBN4096BS (olcegepant), an IV specific & potent
CRGP receptor antagonist, shown in proof-of-concept trial published in 2004 to be effective and well-tolerated
TELCEGEPANT multicentre phase III R-PT-PC-DB-T of MK-0794
(telcagepant) oral 150/300 mg vs zolmitriptan 5 mg & placebo, published in The Lancet in December 2008
GLUTAMATE RECEPTOR ANTAGONISTS
glutamate central in sensory & nociceptive systems throughout the CNS glutamate neurons in trigeminal ganglia express
predominately 5-HT1B/1D/1F receptors 3 subtypes of ionotropic glutamate receptors
(iGluR): NDMA, AMPA, kainate LY-293558 (tezampanel), an AMPA/kainate
antagonist, as effective as sumatriptan vs placebo other iGluR antagonists in Phase II trials metabotropic GluR antagonists may also be
effective recent successful proof-of-concept trial of
ADX10059, a mGluR5 antagonist
TRPV1 ANTAGONISTS
TRPV1 receptors (activated by capsaicin) are found peripherally and centrally some trigeminal TRPV1 receptors may co-locate
with CGRP receptors: ?involved in trigeminally-mediated sensitization
SB-705498, a TRPV1antagonist, in phase II studies
NITRIC OXIDE SYNTHESIS
Nitric oxide (NO) is produced from nitric oxide synthetase (NOS): endothelial, neuronal & inducible NO may activate trigeminovascular fibres &
release CGRP prolonged administration of triptans increases
nNOS, CGRP & cutaneous allodynia GW274150, a selective iNOS inhibitor, was not
effective against migraine NXN-188, a nNOS inhibitor & 5HT1B/1D agonist has
shown more positive results in Phase II
PROSTANOID RECEPTOR ANTAGONISTS
prostaglandin E2 mediates pain and inflammation prostanoids induce CGRP release in animal
models PGE2 levels are elevated in jugular venous blood
in acute migraine attacks PGE2 acts through prostanoid receptors: EP4 is
involved in cerebral vasular dilatation BGC20-1531, an EP4 receptor antagonist, is in
phase II studies will such compounds be more effective than
aspirin or the NSAIDs, which inhibit cyclo-oxygenase and thereby the production of prostaglandins?
THE MIGRAINE PHOENIX: DHE
an old Rx: mode of action unclear DHE currently available only by IV infusion Migranal (DHE/caffeine combination) was
available in the UK in the early 1990s but failed vs triptans because of inconsistent results & poor tolerability
novel delivery methods are now being trialled: inhaled (MAP-004 - LEVADEX©) now shown to be
effective in phase III trials, with a trend towards better sustained pain freedom than triptans
intranasal
YET MORE TRIPTAN CHOICES
sumatriptan was originally available as s/c injection
oral formulations followed rapidly, and more recently ‘melts’ and nasal sprays
Sumatriptan is now out of patent needle-free injection (Intraject) transdermal patches (Zelrix) new delivery options (Optinose) combination with naproxen
(SUM 85 mg NAP 500 mg)
TRANSCRANIAL MAGNETIC STIMULATION
TMS devices deliver a brief magnetic pulse to the scalp and underlying cortex, altering firing patterns
targets cortical spreading depression (CSD) CSD is a wave of
excitation followedby a wave ofinhibition
TMS FOR MIGRAINE
R, DB, parallel-group, sham-controlled trial of single-pulse TMS for MA published in Lancet Neurology in 2010 significantly higher pain freedom seen with sTMS
at 2, 24 and 48 hours than with sham treatment
IN SUMMARY, THEREFORE...the future’s bright
(though not too bright, please)
THANK YOU